GlassScriptPhysician profile
Kimberly Willingham
NPI 1730349705
$683.32
in general payments reported to CMS, 2019-2025
10 companies · $83.64 in 2025
The $83.64 reported for 2025 was more than what a typical Dentist provider received nationally (typical 2025 total: $70.27).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.35 · 2020: $149 · 2021: $116 · 2022: $111 · 2023: $107 · 2024: $95.29 · 2025: $83.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $292.63 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $120.75 | 2021-2025 | Invega Sustenna, Spravato |
| Hu-Friedy Mfg. Co., LLC | $80.00 | 2020 | |
| Bioxcel Therapeutics, INC. | $43.58 | 2023 | Igalmi |
| Otsuka America Pharmaceutical, INC. | $37.71 | 2025 | Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $27.07 | 2024 | Fanapt |
| Jazz Pharmaceuticals INC. | $24.15 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.22 | 2021 | |
| Greenwich Biosciences, INC. | $17.17 | 2021 | |
| Neurelis, INC. | $17.04 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Willingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.